Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 111 followers
Latest posts
Last updated about 19 hours ago
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
about 19 hours ago
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to...
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
2 days ago
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with...
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
6 days ago
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
6 days ago
The opinion will now be referred to the European Commission for final...
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
7 days ago
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly and Verve announce expiration of Verve tender offer
7 days ago
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
22 days ago
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the...
FDA approves updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients
about 1 month ago
INDIANAPOLIS, JUNE 25, 2025 – Eli Lilly and Company (NYSE: LLY) announced...
Lilly declares third-quarter 2025 dividend
about 1 month ago
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of...
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
about 1 month ago
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4...
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
about 1 month ago
The investigational once-daily pill lowered A1C by an average of 1.3% to...
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
about 1 month ago
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a...